MEXICO · COMPANY RESULTS
Key Facts
- The country Mexico is Latin America’s second-largest economy and the biggest trading partner of the United States.
- What happened Genomma Lab Internacional, a Mexican maker of medicines and personal care brands, posted third-quarter 2026 results on Wednesday 21 October.
- The profit Genomma Lab profit rose 18.6% to 514.9 million pesos (about US$27.6 million), or 0.51 pesos a share (about US$0.03).
- The sales Net sales rose 1.3% to 4,497.6 million pesos (about US$241.4 million), with US sales down 30.5%.
- The margin EBITDA fell 10.3% to 944.9 million pesos (about US$50.7 million), a margin of 21.0%.
- Power Index Mexico ranks 2nd of 14 in The Rio Times Latin America Power Index, with 71.4 points (October 2026 edition).
- What it means for you The profit gain came from lower financing costs and a currency gain, while US sales kept shrinking.
Genomma Lab profit rose 18.6% to 514.9 million pesos (about US$27.6 million) in the third quarter of 2026, the company said on Wednesday 21 October. The Mexican group, profiled in its Company Intelligence page, sells medicines, drinks and personal care brands in 18 countries.
US readers will notice the weak spot, with sales to Hispanic shoppers in the United States down 30.5%. Genomma Lab profit works out at 0.51 pesos a share (about US$0.03), up from 0.43 pesos (about US$0.02) a year earlier.
What the Quarterly Report Shows
Net sales were 4,497.6 million pesos (about US$241.4 million at 18.63 pesos to the US dollar on 22 October 2026). That is 1.3% above the 4,441.4 million pesos (about US$238.4 million) of a year earlier.
Gross profit slipped 2.6% to 2,762.1 million pesos (about US$148.2 million), and the gross margin fell to 61.4% from 63.9%. EBITDA, which is operating profit before depreciation and amortisation, fell 10.3% to 944.9 million pesos (about US$50.7 million).
The EBITDA margin narrowed to 21.0% from 23.7%, which the company called a deliberate choice to spend more on promotions and sales. Net profit rose 18.6% to 514.9 million pesos (about US$27.6 million), against 434.1 million pesos (about US$23.3 million) a year earlier.
Earnings per share came to 0.51 pesos (about US$0.03), up from 0.43 pesos (about US$0.02). Genomma Lab profit per share therefore rose by the same 18.6%.
Why Genomma Lab Profit Rose While Operating Profit Fell
The Genomma Lab profit gain came from below the operating line, not from selling more. Financial expenses dropped 32.1% to 130.2 million pesos (about US$7.0 million) after the company refinanced its debt.
A currency swing also helped, with a foreign-exchange gain of 41.1 million pesos (about US$2.2 million). A year earlier the company booked a loss of 122.7 million pesos (about US$6.6 million).
Operating profit itself fell 10.8% to 863.6 million pesos (about US$46.4 million). The company says it chose to invest in growth rather than protect margins.
Mexico, Latin America and the US Hispanic Market
Sales in Mexico fell 2.4% to 2,181.8 million pesos (about US$117.1 million). That is the third straight quarter of improvement after a 22.1% drop in late 2025.
Chief executive Marco Sparvieri said sales to consumers in Mexico returned to growth. The company says it held or gained market share in every business unit despite weak consumer demand.
Latin America outside Mexico grew 12.2% to 2,055.3 million pesos (about US$110.3 million). Argentina rose 39.2% on share gains and hyperinflation accounting.
Excluding Argentina, the region grew 1.6% as Brazilian retailers cut inventories ahead of a tax reform. The company expects Brazilian orders to normalise in the first quarter of 2027.
Sales in the United States fell 30.5% to 260.5 million pesos (about US$14.0 million). The company blamed weak Hispanic retail stores and the destruction of returned product, and it is reshaping its US distribution model.
Drinks Surge as Medicines and Personal Care Slip
Beverages jumped 58.8% to 699.1 million pesos (about US$37.5 million). The Suerox electrolyte drink reached a record 12.6% value share at the company’s largest customer.
Infant nutrition rose 33.9% to 207.3 million pesos (about US$11.1 million). Over-the-counter medicines, the largest unit, fell 5.0% to 2,390.4 million pesos (about US$128.3 million).
Personal care fell 9.7% to 1,200.9 million pesos (about US$64.5 million). The company also cited Mexico’s new tax on drinks with non-caloric sweeteners as a cost.
Cash, Debt and Dividend
Free cash flow rose 52% to 470 million pesos (about US$25.2 million) from 309 million pesos (about US$16.6 million). Net debt stood at 5,242 million pesos (about US$281.4 million), or 1.4 times EBITDA.
Cash totalled 2,760.9 million pesos (about US$148.2 million). Short-term debt fell 63% to 1,185 million pesos (about US$63.6 million) after the long-term refinancing.
On 30 September the company paid a dividend of 0.20 pesos a share (about US$0.01). The total was 194.7 million pesos (about US$10.4 million), and quarterly payments are planned.
Leadership Change and Investor Day
On 17 September 2026 the board named founder and chairman Rodrigo Herrera Aspra interim chief executive from 1 January 2027, while he stays chairman. Sparvieri stays involved in the handover until 31 December 2026.
Genomma Lab plans to present its new operating model and an artificial intelligence platform at an investor day in New York on 3 December 2026. The company, which sells in 18 countries, held its earnings call on Thursday 22 October.
What It Means for US Readers
Genomma Lab sells medicines and consumer brands to Hispanic shoppers in Mexico, Latin America and the United States. The 30.5% fall in its US sales shows how fragile that channel has become for Mexican consumer brands.
For investors who follow Mexican stocks, Genomma Lab profit grew while its operating profit fell, according to the company’s own report. Other Mexican companies have posted results in recent days, including Grupo México, and the Genomma Lab Company Intelligence profile holds the background.
What Is Not Known
The company has not said when US sales will stop falling, and it describes its US plan only as a gradual recovery. It expects Brazilian orders to return to normal in the first quarter of 2027.
Excluding the effects of inflation and currency-translation accounting, sales fell 6.2% and Genomma Lab profit rose 20.2% to 697.1 million pesos (about US$37.4 million). All figures here come from the company’s own report, and no outside analyst assessment of the quarter was available.
More: Mexico news in English, every day from The Rio Times.
Frequently Asked Questions
How much profit did Genomma Lab make in the third quarter of 2026?
Genomma Lab profit was 514.9 million pesos (about US$27.6 million), up 18.6% from a year earlier. Earnings per share were 0.51 pesos (about US$0.03).
Did Genomma Lab sales grow?
Net sales rose 1.3% to 4,497.6 million pesos (about US$241.4 million). Genomma Lab sales growth in Latin America outside Mexico offset weaker sales in Mexico and the United States.
Why did Genomma Lab profit rise if EBITDA fell?
EBITDA fell 10.3% because the company spent more on promotions and sales. Net profit rose because financial costs dropped and a currency swing turned from a loss into a gain.
What is happening with Genomma Lab in the United States?
US sales fell 30.5% to 260.5 million pesos (about US$14.0 million). The company blames weak Hispanic retail and the destruction of returned product.
Who will run Genomma Lab next year?
Founder and chairman Rodrigo Herrera Aspra becomes interim chief executive on 1 January 2027 and stays chairman. Marco Sparvieri stays involved in the handover until 31 December 2026.
Sources: Genomma Lab Investor Relations, third-quarter 2026 report, 21 October 2026; Genomma Lab Investor Relations, CEO transition release, 17 September 2026.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief
In depth
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.